Silence Therapeutics (XRP2) Income Statement
Silence Therapeutics Income Statement
Last quarter (Q2 2026), Silence Therapeutics's total revenue was $0.00, a decrease of 100.00% from the same quarter last year. In Q2, Silence Therapeutics's net income was $-12.29M. See Silence Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 559.00K | $ 43.26M | $ 25.38M | $ 17.65M | $ 12.41M | |
| $ 344.00K | $ 31.45M | $ 15.06M | $ 6.68M | $ 4.96M | |
| $ 90.10M | $ 94.77M | $ 64.66M | $ 56.44M | $ 50.77M | |
| Depreciation and Amortization | $ 555.00K | $ 463.32K | $ 498.00K | $ 490.91K | ― |
| $ -88.05M | $ -49.12M | $ -49.78M | $ -39.93M | ― | |
| $ -89.75M | $ -63.32M | $ -49.60M | $ -49.76M | $ -45.81M | |
| $ 1.15M | $ 18.86M | $ -706.00K | $ 9.29M | $ -42.00K | |
| $ -88.60M | $ -44.46M | $ -50.31M | $ -40.47M | $ -45.86M | |
| $ -88.61M | $ -45.31M | $ -43.27M | $ -41.03M | $ -39.41M | |
| Per Share Metrics | |||||
| Basic EPS | $ -5.67 | $ -2.37 | $ -3.48 | $ -3.78 | $ -1.35 |
| Diluted EPS | $ -5.67 | $ -2.37 | $ -3.48 | $ -3.78 | $ -1.35 |
| Weighted Average Shares Outstanding | 15.74M | 15.42M | 12.36M | 10.73M | 29.65M |
| Weighted Average Shares Outstanding (Diluted) | 15.74M | 15.42M | 12.36M | 10.73M | 29.65M |
Currency in GBP